Biogen Inc. BIIB
Composite 49/100; the shares have moved about 36% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 29/100 — a moderate mark against it.
Momentum ranks 72/100 — a moderate point in its favour. Balance-sheet strength ranks 64/100 — a moderate point in its favour.
Growth ranks 29/100 — a moderate mark against it. Valuation ranks 36/100 — a moderate mark against it. Quality ranks 45/100 — a slight mark against it.
What the company does Biogen discovers, develops, and commercializes therapies for neurological and autoimmune diseases, including multiple sclerosis, spinal muscular atrophy, Alzheimer’s, and biosimilars. Its portfolio spans branded drugs like LEQEMBI for Alzheimer’s and biosimilars such as BENEPALI and IMRALDI.
Key financials Biogen’s profitability metrics are mixed: ROE 4%, ROA 5%, ROCE 4%, and net margin 8%. Revenue grew 1% while EPS fell 21%. Leverage is moderate (Debt/Equity 0.44), but interest coverage is weak at 4x and current ratio is 1.86.
Stock health Momentum is strong over 3m (16%), 6m (14%), and 12m (63%), though it sits 0.27% below its 52-week high. RSI(14) at 65.70 suggests the stock is approaching overbought territory.
Price vs fair value The stock trades at a **discount of 6.30%** to the analyst mean target of 235.57. - Biogen’s Alzheimer’s drug LEQEMBI faces reimbursement headwinds (Real Parkinson’s Disease Hope from Jupiter Neurosciences, Exec Edge). - Biosimilar competition pressures margins (IMRALDI referencing HUMIRA). - Pipeline setbacks in neurology weigh on sentiment (Stoke Therapeutics’ Dravet trial success highlights competitive pressure).
Looking forward Forward P/E of 17x and PEG of 0.15 suggest undemanding valuation, but weak fundamentals (low ROE, high debt) and execution risks in Alzheimer’s and MS remain key watchpoints. Momentum scores (75th percentile) offset quality concerns (45th percentile).
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.